AC-262

A hormone-signaling research chemical. AC-262, AC262 and AC-262536 name the SARM also called Accadrine. It is not a peptide; it acts on the androgen receptor, a signal involved in testosterone's effects. Piu et al. — Pharmacological characterization of AC-262536 (2008) (Animal context · Accessed 2026-09-30) · My experience with AC-262 (Accadrine) (Personal report · Accessed 2026-09-30)

AC-262 is an oral research SARM discussed for muscle, strength and a more energized mood. Reports range from fuller muscles and easier training to anxiety, bloating or little extra progress. Its reputation as a milder SARM does not establish safety or freedom from hormone suppression.

Source context — Piu et al. — Pharmacological characterization of AC-262536 (2008): Abstract only, not full paper; no measured human half-life or recreational efficacy/safety evidence. PubMed direct open showed footer only and Europe PMC returned 403; author institution's complete abstract inspected instead.

Source context — My experience with AC-262 (Accadrine): Cardarine co-use, self-asserted authenticity and commercially linked forum; later OTR-AC is a different identity. Replies include official representatives. Single uncontrolled account.

Fullness and body composition. People seek recomp: adding or retaining muscle while reducing fat. A testosterone user described looking fuller and a favorable body-composition scan after about a month. Their later update reported little strength change; food intake, water and testosterone complicate the muscle-gain claim. AC-262 Experience — first-week mood lift and later updates (Personal report · Accessed 2026-09-30)

A fuller look can accompany little extra strength. The testosterone user's later updates describe weight gain and fullness with no substantial strength gain. These are one person's updates; calories and body scans cannot isolate muscle caused by AC-262. AC-262 Experience — first-week mood lift and later updates (Personal report · Accessed 2026-09-30)

One account: mental lift after the first day. The testosterone-stacked user noticed it after one day and through the first week. Exact minutes-to-onset after swallowing are unstated. AC-262 Experience — first-week mood lift and later updates (Personal report · Accessed 2026-09-30)

Training can feel easier. A Bluelight contributor described improved sit-ups and stair climbing after several weeks at 20 mg/day divided into two doses, without rapid muscle-size growth. This is one experience, not a measured endurance benefit. Bluelight discussion — AC-262 mood and repeated-movement performance (Personal report · Accessed 2026-09-30)

No unusual progress is a real result. The August 2026 poster increased reported amounts from 10 to 25 mg across four weeks without unusual gym progress and reported minor mood swings. Later they recognized pumps but also a sudden loss of workout drive. Replies urging stronger drugs or diagnosing suppression do not verify either explanation. When do the benefits of ACP-262 kick in? (4 weeks in) (Community discussion · Accessed 2026-09-30)

A four-week run disappointed. Jester90210 used 10 mg/day for two weeks, then 20 mg/day for two, with Cardarine: bloating, poor results, no fatigue or weakness. Their later favorable OTR-AC/Cardarine comparison involves a different substance, not a controlled comparison. My experience with AC-262 (Accadrine) (Personal report · Accessed 2026-09-30)

Mild does not mean hormone-neutral. Users disagree about suppression, meaning reduced natural testosterone production. One 20 mg/day contributor reports brain fog, irritability and social withdrawal by week four, but had no blood testing to identify the cause. Lipid changes and uncertain long-term effects remain concerns even when a run feels comfortable. Rad 140 with enclo or ac262 — conflicting suppression accounts (Community discussion · Accessed 2026-09-30)

Anxiety, sleep and stomach effects matter. One user regained muscle after returning to training but planned stopping because of anxiety. Timing threads describe insomnia; the August discussion includes empty-stomach upset. Products and co-used drugs are unverified, so these reports cannot establish incidence or safe combinations. AC 262 — my findings and one interesting thought (Personal report · Accessed 2026-09-30) · AC-262 half life — best guess, early stimulation and insomnia (Community discussion · Accessed 2026-09-30) · When do the benefits of ACP-262 kick in? (4 weeks in) (Community discussion · Accessed 2026-09-30)

Source context — AC-262 Experience — first-week mood lift and later updates: Deleted author; reported 15 mg has no explicit frequency. Testosterone co-use at a reported 175 weekly (opening omits unit), calories, body-scan estimates and supplements confound outcomes. No identity testing or controlled data. Do not count updates as additional users.

Source context — Bluelight discussion — AC-262 mood and repeated-movement performance: Unverified product and uncontrolled performance claims. Thread's opening hypomania/testosterone account belongs to another person and is not an AC-262 event. The 20 mg for 60 days/2 kg goal in #8 is a plan, not an achieved outcome.

Source context — When do the benefits of ACP-262 kick in? (4 weeks in): Title typo ACP-262; body explicitly says Ac262. Brand assertions and taste do not verify identity. Opening weekly quantities omit explicit /day; daily morning schedule appears in follow-up. Later enclomiphene response is uncontrolled, so no efficacy claim for it.

Source context — My experience with AC-262 (Accadrine): Cardarine co-use, self-asserted authenticity and commercially linked forum; later OTR-AC is a different identity. Replies include official representatives. Single uncontrolled account.

Source context — Rad 140 with enclo or ac262 — conflicting suppression accounts: Self-reported laboratory summary lacks report image/units here; adverse account has no bloodwork and cannot diagnose suppression. Enclomiphene claims do not establish a protective regimen.

Source context — AC 262 — my findings and one interesting thought: Return to training after prolonged detraining and prior PED exposure confound muscle regain. No hormone testing. Morning hormone-synchronization claim and subjective zero-suppression claim are unverified.

Source context — AC-262 half life — best guess, early stimulation and insomnia: No measured blood concentrations. Half-life estimate is explicit guess; capsule underdosing and schedule superiority are opinions. Stimulation window is not time to first effect or complete offset.

Oral chart band: about 10–30 mg/day. Forum and vendor templates circulate this daily total, with 10–20 mg/day at the lower end. These are discussion amounts, not a human-tested dose range or escalation plan.

Daily totals and an amount with unstated frequency. The anxiety account used 10 mg/day each morning; the testosterone-stacked account reported 15 mg without explicit frequency. Another user split 20 mg/day and developed brain fog by week four. Twenty daily is not twenty at each administration. AC 262 — my findings and one interesting thought (Personal report · Accessed 2026-09-30) · AC-262 Experience — first-week mood lift and later updates (Personal report · Accessed 2026-09-30) · Rad 140 with enclo or ac262 — conflicting suppression accounts (Community discussion · Accessed 2026-09-30)

Training can feel easier. A Bluelight contributor described improved sit-ups and stair climbing after several weeks at 20 mg/day divided into two doses, without rapid muscle-size growth. This is one experience, not a measured endurance benefit. Bluelight discussion — AC-262 mood and repeated-movement performance (Personal report · Accessed 2026-09-30)

Single and split schedules both appear. One contributor describes 10 mg in a single morning dose, but split daily totals of 25 or 30 mg on other runs. Their preference for liquids over capsules is personal experience; it establishes neither better absorption nor a necessary schedule. AC-262 half life — best guess, early stimulation and insomnia (Community discussion · Accessed 2026-09-30)

Source context — AC 262 — my findings and one interesting thought: Return to training after prolonged detraining and prior PED exposure confound muscle regain. No hormone testing. Morning hormone-synchronization claim and subjective zero-suppression claim are unverified.

Source context — AC-262 Experience — first-week mood lift and later updates: Deleted author; reported 15 mg has no explicit frequency. Testosterone co-use at a reported 175 weekly (opening omits unit), calories, body-scan estimates and supplements confound outcomes. No identity testing or controlled data. Do not count updates as additional users.

Source context — Rad 140 with enclo or ac262 — conflicting suppression accounts: Self-reported laboratory summary lacks report image/units here; adverse account has no bloodwork and cannot diagnose suppression. Enclomiphene claims do not establish a protective regimen.

Source context — Bluelight discussion — AC-262 mood and repeated-movement performance: Unverified product and uncontrolled performance claims. Thread's opening hypomania/testosterone account belongs to another person and is not an AC-262 event. The 20 mg for 60 days/2 kg goal in #8 is a plan, not an achieved outcome.

Source context — AC-262 half life — best guess, early stimulation and insomnia: No measured blood concentrations. Half-life estimate is explicit guess; capsule underdosing and schedule superiority are opinions. Stimulation window is not time to first effect or complete offset.

One account: mental lift after the first day. The testosterone-stacked user noticed it after one day and through the first week. Exact minutes-to-onset after swallowing are unstated. AC-262 Experience — first-week mood lift and later updates (Personal report · Accessed 2026-09-30)

Training changes may take days or remain absent. An August 2026 commenter noticed fuller muscles and pumps within ten days at a reported 15 mg, but no extra gym benefit. The opening poster reported ordinary progress after 28 days, later recognizing stronger pumps around week two. Pump, mood and strength need separate timelines. When do the benefits of ACP-262 kick in? (4 weeks in) (Community discussion · Accessed 2026-09-30)

One report: stimulation for the first 2–3 hours. The 2024 timing contributor describes that early window after dosing, without measuring the full effect's end. Another person reports sleep difficulty that night after a single 20 mg morning dose. A short stimulating feeling does not imply short sleep disruption. AC-262 half life — best guess, early stimulation and insomnia (Community discussion · Accessed 2026-09-30)

Beyond 24 hours appears in a different account. The 2025 opening poster reports lingering focus, workout effects and insomnia. Others describe weaker effects the next day. Amounts and offset measurements are incomplete; no dependable single-dose duration or predictable retention of gains after stopping emerges. AC 262 Half Life — competing estimates and next-day feelings (Community discussion · Accessed 2026-09-30)

About 12 hours is a contributor's estimate. In 2024 VinnTrilloquist calls it a best guess; in 2025 the same contributor states it more confidently. Neither thread supplies human blood measurements. A different comment repeats 12–18 hours. These remain circulated estimates, not an established human half-life. AC-262 half life — best guess, early stimulation and insomnia (Community discussion · Accessed 2026-09-30) · AC 262 Half Life — competing estimates and next-day feelings (Community discussion · Accessed 2026-09-30)

Longer-lasting feelings do not settle clearance. The 2025 poster argues for more than 24 hours because focus and insomnia remained noticeable. Feeling something the next day cannot measure how quickly the compound's blood level halves. Split dosing, comparisons with other SARMs and bowel transit cannot establish it either. AC 262 Half Life — competing estimates and next-day feelings (Community discussion · Accessed 2026-09-30)

Source context — AC-262 Experience — first-week mood lift and later updates: Deleted author; reported 15 mg has no explicit frequency. Testosterone co-use at a reported 175 weekly (opening omits unit), calories, body-scan estimates and supplements confound outcomes. No identity testing or controlled data. Do not count updates as additional users.

Source context — When do the benefits of ACP-262 kick in? (4 weeks in): Title typo ACP-262; body explicitly says Ac262. Brand assertions and taste do not verify identity. Opening weekly quantities omit explicit /day; daily morning schedule appears in follow-up. Later enclomiphene response is uncontrolled, so no efficacy claim for it.

Source context — AC-262 half life — best guess, early stimulation and insomnia: No measured blood concentrations. Half-life estimate is explicit guess; capsule underdosing and schedule superiority are opinions. Stimulation window is not time to first effect or complete offset.

Source context — AC 262 Half Life — competing estimates and next-day feelings: Same VinnTrilloquist as 2024, not independent confirmation. No blood measurements. Caffeine elimination, bowel motility, ACP-105 analogy and felt insomnia cannot measure AC-262 half-life. Author claims many reports without providing them; no invented count adopted.

Four-week accounts; 6–8-week chart patterns. Reports include a four-week Cardarine-stacked run, older 4–8-week talk and a separate 6–8-week chart pattern. Weeks-off discussions do not establish hormone recovery or a safe calendar.

Post-cycle therapy is disputed. PCT means taking other drugs in an attempt to restore hormone production after a course. Enclomiphene appears in these debates, but feeling well or adding it does not establish absence of suppression. The anxious user's training-days-only idea was a future plan, not a completed successful schedule. Rad 140 with enclo or ac262 — conflicting suppression accounts (Community discussion · Accessed 2026-09-30) · AC 262 — my findings and one interesting thought (Personal report · Accessed 2026-09-30)

Source context — Rad 140 with enclo or ac262 — conflicting suppression accounts: Self-reported laboratory summary lacks report image/units here; adverse account has no bloodwork and cannot diagnose suppression. Enclomiphene claims do not establish a protective regimen.

Source context — AC 262 — my findings and one interesting thought: Return to training after prolonged detraining and prior PED exposure confound muscle regain. No hormone testing. Morning hormone-synchronization claim and subjective zero-suppression claim are unverified.

Rarely first-line: More experimental than Ostarine/RAD in older comparison talk. Checked accounts include testosterone co-use and a separate Cardarine stack, so their outcomes cannot be isolated to AC-262. [community]

Oral products, separate from stacks. Accounts describe swallowed research products; the label does not confirm the contents. Testosterone, Cardarine and enclomiphene are separate substances, not AC-262 forms. Their effects make a stack harder to interpret. When do the benefits of ACP-262 kick in? (4 weeks in) (Community discussion · Accessed 2026-09-30)

Post-cycle therapy is disputed. PCT means taking other drugs in an attempt to restore hormone production after a course. Enclomiphene appears in these debates, but feeling well or adding it does not establish absence of suppression. The anxious user's training-days-only idea was a future plan, not a completed successful schedule. Rad 140 with enclo or ac262 — conflicting suppression accounts (Community discussion · Accessed 2026-09-30) · AC 262 — my findings and one interesting thought (Personal report · Accessed 2026-09-30)

Source context — When do the benefits of ACP-262 kick in? (4 weeks in): Title typo ACP-262; body explicitly says Ac262. Brand assertions and taste do not verify identity. Opening weekly quantities omit explicit /day; daily morning schedule appears in follow-up. Later enclomiphene response is uncontrolled, so no efficacy claim for it.

Source context — Rad 140 with enclo or ac262 — conflicting suppression accounts: Self-reported laboratory summary lacks report image/units here; adverse account has no bloodwork and cannot diagnose suppression. Enclomiphene claims do not establish a protective regimen.

Source context — AC 262 — my findings and one interesting thought: Return to training after prolonged detraining and prior PED exposure confound muscle regain. No hormone testing. Morning hormone-synchronization claim and subjective zero-suppression claim are unverified.

Mild does not mean hormone-neutral. Users disagree about suppression, meaning reduced natural testosterone production. One 20 mg/day contributor reports brain fog, irritability and social withdrawal by week four, but had no blood testing to identify the cause. Lipid changes and uncertain long-term effects remain concerns even when a run feels comfortable. Rad 140 with enclo or ac262 — conflicting suppression accounts (Community discussion · Accessed 2026-09-30)

Anxiety, sleep and stomach effects matter. One user regained muscle after returning to training but planned stopping because of anxiety. Timing threads describe insomnia; the August discussion includes empty-stomach upset. Products and co-used drugs are unverified, so these reports cannot establish incidence or safe combinations. AC 262 — my findings and one interesting thought (Personal report · Accessed 2026-09-30) · AC-262 half life — best guess, early stimulation and insomnia (Community discussion · Accessed 2026-09-30) · When do the benefits of ACP-262 kick in? (4 weeks in) (Community discussion · Accessed 2026-09-30)

Official SARM warnings apply as class context. FDA says SARMs are unapproved drugs and cannot legally be marketed in the U.S. as dietary supplements or drugs. Its warnings include liver injury, cardiovascular events, sexual dysfunction, infertility and pregnancy miscarriage. These are class warnings, not measured AC-262-specific risk rates. FDA Warns of Use of SARMs Among Teens, Young Adults (Official context · Accessed 2026-09-30)

Serious symptoms need medical care. Chest pain, severe allergic symptoms, sudden neurological changes or uncontrolled blood pressure or glucose require medical assessment. Forum explanations and additional compounds are not a substitute. Long-term safety and interactions for uncertain research-product contents remain unresolved.

Source context — Rad 140 with enclo or ac262 — conflicting suppression accounts: Self-reported laboratory summary lacks report image/units here; adverse account has no bloodwork and cannot diagnose suppression. Enclomiphene claims do not establish a protective regimen.

Source context — AC 262 — my findings and one interesting thought: Return to training after prolonged detraining and prior PED exposure confound muscle regain. No hormone testing. Morning hormone-synchronization claim and subjective zero-suppression claim are unverified.

Source context — AC-262 half life — best guess, early stimulation and insomnia: No measured blood concentrations. Half-life estimate is explicit guess; capsule underdosing and schedule superiority are opinions. Stimulation window is not time to first effect or complete offset.

Source context — When do the benefits of ACP-262 kick in? (4 weeks in): Title typo ACP-262; body explicitly says Ac262. Brand assertions and taste do not verify identity. Opening weekly quantities omit explicit /day; daily morning schedule appears in follow-up. Later enclomiphene response is uncontrolled, so no efficacy claim for it.

Source context — FDA Warns of Use of SARMs Among Teens, Young Adults: Class-level public warning; does not give an AC-262-specific incidence, dose, half-life or individualized risk estimate.